Medicenna Therapeutics Corp
TSX:MDNA

Watchlist Manager
Medicenna Therapeutics Corp Logo
Medicenna Therapeutics Corp
TSX:MDNA
Watchlist
Price: 0.97 CAD 5.43% Market Closed
Market Cap: 75.9m CAD

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
CA$0
/
CA$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
CA$0
/
CA$0

Peer Comparison

Country Company Market Cap Operating
Margin
CA
Medicenna Therapeutics Corp
TSX:MDNA
80.9m CAD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385.5B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
186.7B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
162.9B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.7B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.8B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Medicenna Therapeutics Corp
Glance View

Market Cap
75.9m CAD
Industry
Biotechnology

Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 13 full-time employees. The company went IPO on 2015-07-13. The firm is primarily engaged in the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its Bi-functional SuperKine ImmunoTherapies (BiSKITs) platform is designed to enable the ability of Superkines to treat immunologically cold tumors. The Company’s product candidate MDNA55, is an Empowered Superkine developed as a therapeutic for recurrent glioblastoma multiforme (rGBM), a fatal form of brain cancer. MDNA11, an IL-2 Superkine that has been fused with human recombinant albumin. The firm has not earned any revenues from its products.

MDNA Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top